In this video interview, Michael Liu, discusses the need for continued monitoring of these medical research cuts to gain a better understanding of exactly what trials they are impacting.
In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed a recent study on National Institutes of Health (NIH) grant cuts. Among other notable findings, the study highlighted that 20% of terminated grants were early career training grants, which are crucial for maintaining biomedical research pipelines. Liu also highlighted how the cuts have disproportionately affected institutions nationwide and compromised ongoing clinical trials, particularly those involving marginalized populations.
ACT: What do you think the future holds for the clinical research industry amidst the funding cuts?
Liu: I think it remains to be seen. One essential thing is just continued data monitoring and transparency from the government. I think that's one of the biggest things that we hope that our study is a call to action for. It's a really great step that the administration has put out this database of terminator grants, but there's so much more, making it easily accessible to pick out which ones are clinical trials and what topic areas of these trials they are. I think that's critically important. As all of you know, the NIH is publicly funded, and as the public, we deserve to have the knowledge. I think beyond that, also understanding what are the reasons behind grand terminations. That is a huge limitation that we don't understand. It doesn't give researchers and trialists the opportunity to respond to be able to make adjustments to whatever their projects are. I think that's an important next step. I think we just need to continue to monitor what's going on and what the impact will be on the clinical research landscape.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.